Immunome (IMNM) Income from Continuing Operations (2019 - 2026)
Immunome (IMNM) reported Income from Continuing Operations of 59331000.0 for Q1 2026, down 32.92% on a YoY basis from 88450569.99 in Q1 2025, and up 18.57% quarter-over-quarter from 72861000.0 in Q4 2025.
Immunome (IMNM) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Immunome has reported Income from Continuing Operations for 8 years, with the latest figure at 59331000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 32.92% year-over-year to 59331000.0; the trailing twelve-month figure through Mar 2026 stood at 238808000.0 (down 9.48% YoY), and the FY2025 full-year result was 224113000.0, up 26.71% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 59331000.0, up from 72861000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 4471000.0 in Q1 2023, with the low at 132299000.0 in Q1 2024.
- Historically, Income from Continuing Operations has averaged 43275000.0 across 5 years, with a median of 44636000.0 in 2025.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations sank 2859.05% — and 2025, when it soared 66.26%.
- Immunome's Income from Continuing Operations stood at 7787000.0 in 2022, then plunged by 1115.53% to 94653000.0 in 2023, then advanced by 12.34% to 82970000.0 in 2024, then advanced by 12.18% to 72861000.0 in 2025, then climbed by 18.57% to 59331000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 59331000.0 (Q1 2026), 72861000.0 (Q4 2025), and 60138000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Immunome | 2.12 Bn | 1.54 Bn | - | -59.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -59.33 Mn |
| Dec 31, 2025 | -72.86 Mn |
| Sep 30, 2025 | -60.14 Mn |
| Jun 30, 2025 | -46.48 Mn |
| Mar 31, 2025 | -44.64 Mn |
| Dec 31, 2024 | -82.97 Mn |
| Sep 30, 2024 | -50.52 Mn |
| Jun 30, 2024 | -40.01 Mn |
| Mar 31, 2024 | -132.30 Mn |
| Dec 31, 2023 | -94.65 Mn |
| Sep 30, 2023 | -4.63 Mn |
| Jun 30, 2023 | -5.77 Mn |
| Mar 31, 2023 | -4.47 Mn |
| Dec 31, 2022 | -7.79 Mn |
| Sep 30, 2022 | -8.53 Mn |
| Jun 30, 2022 | -8.93 Mn |
| Mar 31, 2022 | -11.65 Mn |
| Dec 31, 2021 | -7.84 Mn |
| Sep 30, 2021 | -7.72 Mn |
| Jun 30, 2021 | -5.74 Mn |